{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Choice&page=4", "query": { "intervention": "Positive Choice", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 499, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Choice&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positive+Choice&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T22:16:27.640Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07558733", "title": "Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HR+ HER2- Breast Cancer" ], "interventions": [ { "name": "Serabelisib", "type": "DRUG" }, { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Faeth Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-04-22", "completion_date": "2033-05", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 7, "location_summary": "Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Springfield", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07558733" }, { "nct_id": "NCT05264415", "title": "Intergenerational Transmission of Traumatic Stress", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stress, Psychological", "Stress Disorders, Traumatic", "Emotion Regulation", "Behavior, Child", "Emotional Stress", "Trauma, Psychological", "Anxiety", "Depression", "Coping Skills", "Parent-Child Relations", "Parenting" ], "interventions": [ { "name": "Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC)", "type": "BEHAVIORAL" }, { "name": "Parenting Education Website", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 65, "start_date": "2021-10-06", "completion_date": "2024-11-04", "has_results": false, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05264415" }, { "nct_id": "NCT05467891", "title": "Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locoregional Recurrence", "Hormone Receptor-positive Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oana Danciu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2022-09-13", "completion_date": "2029-08-15", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05467891" }, { "nct_id": "NCT05243862", "title": "Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "PolyPEPI1018", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Treos Bio Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-06-02", "completion_date": "2025-01-14", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243862" }, { "nct_id": "NCT06865196", "title": "Investigating a Brief Virtual Seminar Series for Parents of Teens Ages 13-17", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Positive Parenting Skills" ], "interventions": [ { "name": "Positive Parenting Seminar Series", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Texas Tech University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 185, "start_date": "2024-10-17", "completion_date": "2026-07-14", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 1, "location_summary": "Lubbock, Texas", "locations": [ { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06865196" }, { "nct_id": "NCT07225452", "title": "An Exosomal miRNA-based Liquid Biopsy for ICC Detection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Intrahepatic Cholangiocarcinoma (Icc)" ], "interventions": [ { "name": "Small RNA sequencing", "type": "DIAGNOSTIC_TEST" }, { "name": "LUMIC assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 535, "start_date": "2024-06-21", "completion_date": "2026-02-05", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07225452" }, { "nct_id": "NCT04082364", "title": "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "HER2-positive Gastric Cancer" ], "interventions": [ { "name": "margetuximab", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Tebotelimab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2019-09-30", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 28, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 25 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04082364" }, { "nct_id": "NCT04162847", "title": "Harnessing Mobile Technology to Reduce Mental Health Disorders in College Populations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety Disorders", "Depressive Disorder", "Eating Disorders" ], "interventions": [ { "name": "SilverCloud Health Intervention", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6205, "start_date": "2019-10-07", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 4, "location_summary": "Palo Alto, California • Ann Arbor, Michigan • St Louis, Missouri + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "State College", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04162847" }, { "nct_id": "NCT06797635", "title": "Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Epirubicin hydrochloride", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 372, "start_date": "2025-03-20", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 8, "location_summary": "Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Billings", "state": "Montana" }, { "city": "Tigard", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06797635" }, { "nct_id": "NCT06633900", "title": "Naltrexone for Overdose Prevention", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Overdose Accidental" ], "interventions": [ { "name": "IM naltrexone", "type": "DRUG" }, { "name": "Usual Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-04-10", "completion_date": "2027-04-15", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-29T22:16:27.640Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06633900" } ] }